Nitroglycerin
- Half-Life (t½)
- SL: 2m · IV: 2m
- Formula
- C3H5N3O9
- Molecular Weight
- 227.09 g/mol
- Aliases
- GTN, Nitrostat, Nitro-Dur
Pharmacological Mechanism
Prodrug → intracellular reduction (mitochondrial ALDH-2) releases nitric oxide → guanylyl cyclase activation → cGMP → smooth muscle relaxation. Predominantly venous dilation (decreases preload) at low doses; coronary + arteriolar dilation at higher doses. Tolerance develops within 24 h of continuous exposure — nitrate-free interval essential.
Half-Life & Elimination Curve (SL: 2m · IV: 2m)
Elimination (SL)
- 0×t½0h100% (0.254 µg/L)
- 1×t½2m50% (0.127 µg/L)
- 2×t½5m25% (0.0636 µg/L)
- 3×t½7m12.5% (0.0318 µg/L)
- 4×t½10m6.3% (0.0159 µg/L)
- 5×t½12m3.1% (0.00795 µg/L)
Dosing Guidelines
- Sublingual (SL): Typical 137 mcg (Range: 5–400 mcg)
- Transdermal (TD): Typical 137 mcg (Range: 5–400 mcg)
- Intravenous (IV): Typical 137 mcg (Range: 5–400 mcg)
- Intranasal (IN): Typical 137 mcg (Range: 5–400 mcg)
Pharmacokinetic Parameters
- Sublingual (SL): Bioavailability (F): 39% · Volume of Distribution (Vd): 210 L [PMID 3925750]
- Intravenous (IV): Bioavailability (F): 100% · Volume of Distribution (Vd): 210 L [PMID 3925750]
Pathways It Modulates
Target Organ Systems
Interactions
- NAC (caution): NAC potentiates nitrate-induced hypotension via denitration pathway. [Horowitz 1988]
Chemical Structure & Identifiers
- InChIKey: SNIOPGDIGTZGOP-UHFFFAOYSA-N
- SMILES: C(C(CO[N+](=O)[O-])O[N+](=O)[O-])O[N+](=O)[O-]
References